Provectus Biopharmaceuticals, Inc.
Moat Score — Provectus Biopharmaceuticals, Inc.
Total Moat Score
3 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Provectus holds patents around pharmaceutical-grade rose bengal sodium (RBS) that distinguish it from the non-pharmaceutical-grade rose bengal used by outside researchers, giving it a real but narrow IP position reused across PV-10, PH-10, and PV-305 rather than a broad patent estate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage company with no approved product and a working capital deficiency of roughly $6 million, Provectus has no manufacturing or distribution cost advantage over any other small biotech; if anything, its thin cash position is a structural disadvantage versus better-funded immuno-oncology developers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no FDA-approved product and no history of substantial commercial revenue, the company has no demonstrated pricing power; any future pricing power is purely speculative and contingent on regulatory approval years away. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Intratumoral and topical drug therapies built on a single small molecule generate no network effect; clinical adoption of PV-10 or PH-10 by one physician or institution does not make the product more valuable to the next. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 0 / 5 | There is no approved, in-use product today, so no physician or patient switching cost exists yet; even if approved, localized injectable or topical therapies for oncology/dermatology typically carry low switching costs versus established standards of care. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Reusing one proprietary molecule (RBS) across oncology, dermatology, and ophthalmology formulations gives some R&D efficiency versus pursuing unrelated chemical entities, but the company's sub-$1 million cash position and dependence on a small government grant show it operates well below any efficient scale in clinical development. |